A. Collier Smyth, M.D.
A. Collier Smyth, M.D. joined our board of directors in April 2009, following
his retirement from Bristol-Myers Squibb Company, or BMS, where he served as Senior Vice President of
Medical Strategy, Oncology. Prior to his recent retirement from BMS, Dr. Smyth led oncology medical affairs in
the United States, including the U. S. life-cycle development of paclitaxel (Taxol®), carboplatin (Paraplatin®)
and ifosfamide (Ifex®). Most recently, he participated in the launch of multiple BMS oncology drugs,
including cetuximab (Erbitux®), dasatinib (Sprycel®) and ixabepilone (Ixempra®).
During his thirteen-year tenure with BMS, Dr. Smyth oversaw key aspects of medical strategy, medical liaison,
medical information, clinical operations, regulatory affairs, quality assurance and compliance in
the oncology division of BMS. At times, medical affairs for virology and immunoscience were added to his
oncology responsibilities. Prior to joining BMS, Dr. Smyth served as vice president of medical affairs
with American Oncology Resources, Inc., now U.S. Oncology, where he was responsible for establishing the
strategic priorities of the country’s largest oncology physician group practice. Previously, Dr. Smyth was
the founder and president of New Hampshire Oncology/Hematology, the first office-based medical oncology practice
in New Hampshire. Dr. Smyth also serves on the Board of Directors of Ariad Pharmaceuticals, Inc..